Cargando…

Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal

Clinical trials are complicated, time-consuming and costly. From the initial screening, informed consent and recruitment of the participants’ to study completion, the sponsor must undertake a wide array of complex and closely monitored operations, complying with international standards for human sub...

Descripción completa

Detalles Bibliográficos
Autores principales: Saluja, Tarun, Giri, Bishnu Rath, Chaudhary, Shipra, Tamrakar, Dipesh, Kanodia, Piush, Palkar, Sonali, Vemula, Sridhar, Chinaworapong, Suchada, Kim, Bomi, Gupta, Birendra Prasad, Kyoung Jo, Sue, Aspinall, Sanet, Rai, Ganesh Kumar, Steele, Duncan, Kim, Jerome H., Wartel, T. Anh, Sahastrabuddhe, Sushant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189093/
https://www.ncbi.nlm.nih.gov/pubmed/33524278
http://dx.doi.org/10.1080/21645515.2020.1855955
_version_ 1783705445922242560
author Saluja, Tarun
Giri, Bishnu Rath
Chaudhary, Shipra
Tamrakar, Dipesh
Kanodia, Piush
Palkar, Sonali
Vemula, Sridhar
Chinaworapong, Suchada
Kim, Bomi
Gupta, Birendra Prasad
Kyoung Jo, Sue
Aspinall, Sanet
Rai, Ganesh Kumar
Steele, Duncan
Kim, Jerome H.
Wartel, T. Anh
Sahastrabuddhe, Sushant
author_facet Saluja, Tarun
Giri, Bishnu Rath
Chaudhary, Shipra
Tamrakar, Dipesh
Kanodia, Piush
Palkar, Sonali
Vemula, Sridhar
Chinaworapong, Suchada
Kim, Bomi
Gupta, Birendra Prasad
Kyoung Jo, Sue
Aspinall, Sanet
Rai, Ganesh Kumar
Steele, Duncan
Kim, Jerome H.
Wartel, T. Anh
Sahastrabuddhe, Sushant
author_sort Saluja, Tarun
collection PubMed
description Clinical trials are complicated, time-consuming and costly. From the initial screening, informed consent and recruitment of the participants’ to study completion, the sponsor must undertake a wide array of complex and closely monitored operations, complying with international standards for human subject research and local requirements. Conducting these studies in an underdeveloped country, with limited resources, infrastructure, and experience with regulated clinical trials adds to this complexity. The initial site selection, set up and preparatory activities for the clinical trial are crucial to minimizing the risks to both participants and to successful completion during the subsequent study execution. In this paper, we describe the experience and lessons learned of building clinical trial site capacity in terms of infrastructure and human resource development for a Phase III vaccine clinical trial. We believe that sharing the experience of setting up a clinical trial in a resource-limited country will enable other entities contemplating clinical research in these countries, to prepare and plan ahead, to minimize the impact of barriers, and to contribute to bringing more studies to the countries where people live with the burden of vaccine-preventable, poverty-associated diseases.
format Online
Article
Text
id pubmed-8189093
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-81890932021-06-17 Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal Saluja, Tarun Giri, Bishnu Rath Chaudhary, Shipra Tamrakar, Dipesh Kanodia, Piush Palkar, Sonali Vemula, Sridhar Chinaworapong, Suchada Kim, Bomi Gupta, Birendra Prasad Kyoung Jo, Sue Aspinall, Sanet Rai, Ganesh Kumar Steele, Duncan Kim, Jerome H. Wartel, T. Anh Sahastrabuddhe, Sushant Hum Vaccin Immunother Commentary Clinical trials are complicated, time-consuming and costly. From the initial screening, informed consent and recruitment of the participants’ to study completion, the sponsor must undertake a wide array of complex and closely monitored operations, complying with international standards for human subject research and local requirements. Conducting these studies in an underdeveloped country, with limited resources, infrastructure, and experience with regulated clinical trials adds to this complexity. The initial site selection, set up and preparatory activities for the clinical trial are crucial to minimizing the risks to both participants and to successful completion during the subsequent study execution. In this paper, we describe the experience and lessons learned of building clinical trial site capacity in terms of infrastructure and human resource development for a Phase III vaccine clinical trial. We believe that sharing the experience of setting up a clinical trial in a resource-limited country will enable other entities contemplating clinical research in these countries, to prepare and plan ahead, to minimize the impact of barriers, and to contribute to bringing more studies to the countries where people live with the burden of vaccine-preventable, poverty-associated diseases. Taylor & Francis 2021-02-01 /pmc/articles/PMC8189093/ /pubmed/33524278 http://dx.doi.org/10.1080/21645515.2020.1855955 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Saluja, Tarun
Giri, Bishnu Rath
Chaudhary, Shipra
Tamrakar, Dipesh
Kanodia, Piush
Palkar, Sonali
Vemula, Sridhar
Chinaworapong, Suchada
Kim, Bomi
Gupta, Birendra Prasad
Kyoung Jo, Sue
Aspinall, Sanet
Rai, Ganesh Kumar
Steele, Duncan
Kim, Jerome H.
Wartel, T. Anh
Sahastrabuddhe, Sushant
Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal
title Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal
title_full Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal
title_fullStr Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal
title_full_unstemmed Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal
title_short Challenges and opportunities in setting up a phase III vaccine clinical trial in resource limited settings: Experience from Nepal
title_sort challenges and opportunities in setting up a phase iii vaccine clinical trial in resource limited settings: experience from nepal
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8189093/
https://www.ncbi.nlm.nih.gov/pubmed/33524278
http://dx.doi.org/10.1080/21645515.2020.1855955
work_keys_str_mv AT salujatarun challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT giribishnurath challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT chaudharyshipra challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT tamrakardipesh challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT kanodiapiush challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT palkarsonali challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT vemulasridhar challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT chinaworapongsuchada challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT kimbomi challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT guptabirendraprasad challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT kyoungjosue challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT aspinallsanet challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT raiganeshkumar challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT steeleduncan challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT kimjeromeh challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT warteltanh challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal
AT sahastrabuddhesushant challengesandopportunitiesinsettingupaphaseiiivaccineclinicaltrialinresourcelimitedsettingsexperiencefromnepal